This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for dementia and the supporting scientific evidence and updates the 1996 recommendations on this topic. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and the National Guideline Clearinghouse (www.guideline.gov) and in print by subscribing to the Guide to Clinical Preventive Services, Third Edition: Periodic Updates. The cost of this subscription is $60, and it can be ordered through the Agency for Healthcare Research and Quality (AHRQ) Publications Clearinghouse (call 1-800-358-9295 or e-mail ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned. The summary of the evidence is also available in print through the AHRQ Publications Clearinghouse.
See related article on pp 927-937.
SUMMARY OF THE RECOMMENDATION
The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against routine screening for dementia in older adults. This is a grade I recommendation. ( 
CLINICAL CONSIDERATIONS
The Mini-Mental Status Examination (MMSE) is the best-studied instrument for screening for cognitive impairment. When the MMSE is used to screen unselected patients, the predictive value of a positive result is only fair. The accuracy of the MMSE depends on a person's age and educational level: Using an arbitrary cut-point may potentially lead to more false-positives among older people with lower educational levels, and more false-negatives among younger people with higher educational levels. Tests that assess functional limitations rather than cognitive impairment, such as the Functional Activities Questionnaire (FAQ), can detect dementia with sensitivity and specificity comparable to those of the MMSE.
Early recognition of cognitive impairment, in addition to helping make diagnostic and treatment decisions, allows clinicians to anticipate problems the patient may have in understanding and adhering to recommended therapy. This information may also be useful to the patient's caregivers and family members in helping to anticipate and plan for future problems that may develop as a result of progression of cognitive impairment.
Although current evidence does not support routine screening of patients in whom cognitive impairment is not otherwise suspected, clinicians should assess cognitive function whenever cognitive impairment or deterioration is suspected on the basis of direct observation; patient report; or concerns raised by family members, friends, or caretakers.
The brief review of the evidence and other sections that are normally included in USPSTF recommendation statements are available in the complete recommendation and rationale statement on the USPSTF Web site (www .preventiveservices.ahrq.gov).
RECOMMENDATIONS OF OTHERS
No formal recommendations for routine screening for dementia are available. The American Academy of Neurology (1) and the Canadian Task Force on Preventive Health Care (2) conclude that there is insufficient evidence to recommend cognitive screening in asymptomatic individuals. The American Medical Association (3) and the American Academy of Family Physicians (4) recommend that physicians be alert for cognitive and functional decline in elderly patients for recognition of dementia in its early stages. 
